Cargando…

Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota

Emerging evidence supports that the efficacy of immune checkpoint blockade (ICB) therapy is associated with the host’s gut microbiota, as prior antibiotic intake often leads to poor outcome and low responsiveness toward ICB treatment. Therefore, we hypothesized that the efficacy of ICB therapy like...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Guangqi, Ma, Teng, Zhang, Tao, Jin, Hao, Li, Yalin, Kwok, Lai-Yu, Zhang, Heping, Sun, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712698/
https://www.ncbi.nlm.nih.gov/pubmed/34970262
http://dx.doi.org/10.3389/fimmu.2021.772532
_version_ 1784623610456965120
author Gao, Guangqi
Ma, Teng
Zhang, Tao
Jin, Hao
Li, Yalin
Kwok, Lai-Yu
Zhang, Heping
Sun, Zhihong
author_facet Gao, Guangqi
Ma, Teng
Zhang, Tao
Jin, Hao
Li, Yalin
Kwok, Lai-Yu
Zhang, Heping
Sun, Zhihong
author_sort Gao, Guangqi
collection PubMed
description Emerging evidence supports that the efficacy of immune checkpoint blockade (ICB) therapy is associated with the host’s gut microbiota, as prior antibiotic intake often leads to poor outcome and low responsiveness toward ICB treatment. Therefore, we hypothesized that the efficacy of ICB therapy like anti-programmed cell death protein-1 (PD-1) treatment required an intact host gut microbiota, and it was established that probiotics could enhance the recovery of gut microbiota disruption by external stimuli. Thus, the present study aimed to evaluate the effect of the probiotics, Lactobacillus rhamnosus Probio-M9, on recovering antibiotic-disrupted gut microbiota and its impact on the outcome of ICB therapy in tumor-bearing mice. We first disrupted the mouse microbiota by antibiotics and then remediated the gut microbiota by probiotics or naturally. Tumor transplantation was then performed, followed by anti-PD-1-based antitumor therapy. Changes in the fecal metagenomes and the tumor suppression effect were monitored during different stages of the experiment. Our results showed that Probio-M9 synergized with ICB therapy, significantly improving tumor inhibition compared with groups not receiving the probiotic treatment (P < 0.05 at most time points). The synergistic effect was accompanied by effective restoration of antibiotic-disrupted fecal microbiome that was characterized by a drastically reduced Shannon diversity value and shifted composition of dominating taxa. Moreover, probiotic administration significantly increased the relative abundance of beneficial bacteria (e.g., Bifidobacterium pseudolongum, Parabacteroides distasonis, and some Bacteroides species; 0.0001 < P < 0.05). The gut microbiome changes were accompanied by mild reshaping of the functional metagenomes characterized by enrichment in sugar degradation and vitamin and amino acid synthesis pathways. Collectively, this study supported that probiotic administration could enhance the efficacy and responsiveness of anti-PD-1-based immunotherapy, and Probio-M9 could be a potential candidate of microbe-based synergistic tumor therapeutics. The preclinical data obtained here would support the design of future human clinical trials for further consolidating the current findings and for safety assessment of probiotic adjunctive treatment in ICB therapy.
format Online
Article
Text
id pubmed-8712698
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-87126982021-12-29 Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota Gao, Guangqi Ma, Teng Zhang, Tao Jin, Hao Li, Yalin Kwok, Lai-Yu Zhang, Heping Sun, Zhihong Front Immunol Immunology Emerging evidence supports that the efficacy of immune checkpoint blockade (ICB) therapy is associated with the host’s gut microbiota, as prior antibiotic intake often leads to poor outcome and low responsiveness toward ICB treatment. Therefore, we hypothesized that the efficacy of ICB therapy like anti-programmed cell death protein-1 (PD-1) treatment required an intact host gut microbiota, and it was established that probiotics could enhance the recovery of gut microbiota disruption by external stimuli. Thus, the present study aimed to evaluate the effect of the probiotics, Lactobacillus rhamnosus Probio-M9, on recovering antibiotic-disrupted gut microbiota and its impact on the outcome of ICB therapy in tumor-bearing mice. We first disrupted the mouse microbiota by antibiotics and then remediated the gut microbiota by probiotics or naturally. Tumor transplantation was then performed, followed by anti-PD-1-based antitumor therapy. Changes in the fecal metagenomes and the tumor suppression effect were monitored during different stages of the experiment. Our results showed that Probio-M9 synergized with ICB therapy, significantly improving tumor inhibition compared with groups not receiving the probiotic treatment (P < 0.05 at most time points). The synergistic effect was accompanied by effective restoration of antibiotic-disrupted fecal microbiome that was characterized by a drastically reduced Shannon diversity value and shifted composition of dominating taxa. Moreover, probiotic administration significantly increased the relative abundance of beneficial bacteria (e.g., Bifidobacterium pseudolongum, Parabacteroides distasonis, and some Bacteroides species; 0.0001 < P < 0.05). The gut microbiome changes were accompanied by mild reshaping of the functional metagenomes characterized by enrichment in sugar degradation and vitamin and amino acid synthesis pathways. Collectively, this study supported that probiotic administration could enhance the efficacy and responsiveness of anti-PD-1-based immunotherapy, and Probio-M9 could be a potential candidate of microbe-based synergistic tumor therapeutics. The preclinical data obtained here would support the design of future human clinical trials for further consolidating the current findings and for safety assessment of probiotic adjunctive treatment in ICB therapy. Frontiers Media S.A. 2021-12-14 /pmc/articles/PMC8712698/ /pubmed/34970262 http://dx.doi.org/10.3389/fimmu.2021.772532 Text en Copyright © 2021 Gao, Ma, Zhang, Jin, Li, Kwok, Zhang and Sun https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Gao, Guangqi
Ma, Teng
Zhang, Tao
Jin, Hao
Li, Yalin
Kwok, Lai-Yu
Zhang, Heping
Sun, Zhihong
Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
title Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
title_full Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
title_fullStr Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
title_full_unstemmed Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
title_short Adjunctive Probiotic Lactobacillus rhamnosus Probio-M9 Administration Enhances the Effect of Anti-PD-1 Antitumor Therapy via Restoring Antibiotic-Disrupted Gut Microbiota
title_sort adjunctive probiotic lactobacillus rhamnosus probio-m9 administration enhances the effect of anti-pd-1 antitumor therapy via restoring antibiotic-disrupted gut microbiota
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8712698/
https://www.ncbi.nlm.nih.gov/pubmed/34970262
http://dx.doi.org/10.3389/fimmu.2021.772532
work_keys_str_mv AT gaoguangqi adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT mateng adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT zhangtao adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT jinhao adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT liyalin adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT kwoklaiyu adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT zhangheping adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota
AT sunzhihong adjunctiveprobioticlactobacillusrhamnosusprobiom9administrationenhancestheeffectofantipd1antitumortherapyviarestoringantibioticdisruptedgutmicrobiota